CNBX · CNBX Pharmaceuticals Inc.
Market Cap
$224,807
Shares
1.61B
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.00
Avg vol 30d3.4M
Short int1.3M · 0.1% float · 1.0d
Short vol100%
DataMay 2022–Aug 2026
Filing10-Q · Jun 24
Raw chart and full-history price indicators begin at the captured split on May 12, 2022; bars on opposite sides are not compared.
Up next
FQ1-27 quarter ends
~Nov 30, 2026
Est
filed Jun 24, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−67%
below
Price vs 50-day avg
0%
above
RSI (14)
46
neutral
MACD trend
Positive
52-week position
0%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−50%
trailing
YTD return
−75%
this year
Relative strength
−63%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -10.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 4-yr low, contrarian setup
Squeeze score
27
low risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+100%
Y/Y
Quant / Vol
risk profile
Volatility
523%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
100.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−67%
Bearish
Price vs 50-day avg
0%
Neutral
RSI (14)
46
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.08% of float · ▼ -10.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 4-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -67%
vs 50-day avg +0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNBX
this stock
CNBX Pharmaceuticals Inc.
|
$224,807 | -75.0% | -100.0% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Archer Investment Corp
Held
Float
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on May 12, 2022; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNBX | -50.0% | +0.0% | -50.0% | +0.0% | -75.0% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -50.5% | -3.0% | -63.4% | -3.0% | -87.8% |